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Recent advances in wireless communication,
data storage, and implantable electronic technolo-
gies have ushered in a new era of real-time, remo-
te electrocardiographic (ECG) monitoring using
implantable devices. Existing continuous external
ECG monitoring is limited by the patient’s ability
to tolerate adhesive electrodes applied to the skin
for days at a time, and the need to have the device
worn on the waist or around the neck at all times.
These external ambulatory ECG monitoring devi-
ces are first line when limited monitoring are ne-
eded but are impractical for long term use. The in-
corporation of cellular communication technology
to provide real-time, continuous external ECG
monitoring is highlighted by Cardionet’s monitoring
services. In this model, ECG data is continuously
transmitted to a central location via cell phone com-
munication for analysis and reporting [1, 2].
Implantable ECG devices are indicated for pa-
tients requiring long-term monitoring to diagnose
the cause of recurrent syncope or to aid in the acti-
ve management of arrhythmias such as atrial fibril-
lation over prolonged periods of time (months to
years). A key criterion for any implantable ECG
monitor is that it be minimally invasive, reliable,
wireless enabled, and programmable to meet the
individual patient’s diagnostic needs.
While these devices are clearly distinct from
therapeutic devices such as pacemakers and implan-
table cardioverter-defibrillators, the technological
advances of the latter group have facilitated the
emergence of this technology.
In 1998 Medtronic received Food and Drug
Administration approval for the “reveal” implanta-
ble loop recorder (ILR), ushering in the first gene-
ration of automatic implantable ECG recording
technology [3]. The ILR provided physicians with
a powerful tool for managing a specific group of pa-
tients: those with recurrent syncope of unknown
etiology. The ILR platform allows for patient-acti-
vated storage of ECGs and automatic recording trig-
gered by heart rate criteria programmed by the
health provider. Until recently, access to the sto-
red ECG data required an office visit to download
the information. Within the past year remote trans-
telephonic transmission of data has been made po-
ssible, facilitating the exchange of information
between patients and health care providers.
In 2007 Transoma introduced their “sleuth”
implantable ECG monitoring system, which, in ad-
dition to standard automatic and patient-activated
recording of ECG data, has the capability to automa-
tically transmit the data to handheld “personal dia-
gnostic manager” (PDM) [4]. The PDM then esta-
blishes a communication link with, and downloads
data to, a base station in the patient’s home. The base
station then communicates with a monitoring cen-
tre that operates 24-hours a day, seven days a week
to provide interpretation of the arrhythmia. The elec-
trocardiographic data is reviewed by certified tech-
nicians and transmitted to the physician’s office via
fax, e-mail, or telephone. In addition, the active scre-
ening of all ECG data by the technicians reduces the
physician’s office time and the resources required
to sort out artefacts and clinically irrelevant trans-
missions. In this situation, near real-time transmis-
sion of data to a central station is limited to those
times that the patient is at home. Any arrhythmias
occurring outside the home will not be available for
analysis or notification until the patient returns home
and a communication link is made between the pa-
tient’s implanted device and the base station.
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Current clinical guidelines focus on using the-
se devices in patients with unexplained syncope,
near syncope, dizziness, or palpitations. However,
implantable ECG monitors provide clinicians with
a new set of tools that are not limited to diagnostics
but allow long term arrhythmia management. The
incorporation of a small handheld interface for pa-
tients provides an opportunity to develop patient-
specific applications in the future that empower the
patients to play an active role in their own health
care. The potential utility of these technologies in
clinical practice includes the monitoring of arrhy-
thmias such as atrial fibrillation and its response to
pharmacologic, radiofrequency or cryoablation tech-
niques, or device-based therapeutics. In the futu-
re, implantable ECG monitoring devices will pro-
bably play a key role in clinical arrhythmia trials
studying the efficacy of various therapeutic appro-
aches such as pulmonary vein isolation in atrial
fibrillation. The objective continuous control and
post-intervention monitoring of arrhythmias provi-
ded by this technology may facilitate and provide
a much more accurate picture of treatment outcomes
in the long term.
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